OrganiGram Holdings Inc.

Choosing between cannabis stocks Aphria and OrganiGram requires a look at both companies’ track records and outlook for 2021.

On April 5, OrganiGram stock was up after the company announced that it has acquired The Edibles & Infusions. Is OGI stock a good investment?

Marijuana stocks rallied after Joe Biden won the presidential election. What’s the forecast for Organigram stock? Should investors buy the stock?

President Trump hasn’t directly supported or opposed marijuana. In the past, he said that marijuana makes people “lose IQ points.”

In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.

In recent years, vaping devices or e-cigarettes have been considered safer than tobacco cigarettes. However, the rise in vaping is now a matter of concern.

Cannabis legalization is heating up. More states are coming forward to legalize marijuana. Cannabis is also gaining global popularity.

On December 16, Canopy Growth was trading at 26.79 Canadian dollars, implying a rise of 9.6% since its fiscal 2020 second-quarter earnings release.

AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.

Aphria has successfully strengthened its position not only in Canada but also in international markets. The company reported impressive second-quarter results.

Cannabis 2.0 legalization will take place in Canada this month. Aphria plans to expand its consumer base in the vape and concentrates business.

With Biden strongly opposing full-scale legalization, President Trump could turn around things. President Trump might support medical marijuana legalization.

Vaping has become very popular. However, investigations by the FTC and FDA sparked more concerns. Juul’s vaping devices could cause seizures.

Federally, cannabis legalization saw daylight in Canada in 2018. The Cannabis Act legalized recreational marijuana in October 2018. Now, the country is all set for the second wave of legalization, Cannabis 2.0, which includes cannabis edibles, cannabis-infused beverages, extracts, and various other products. Let’s dig into this more. Canada’s second wave of legalization Next month, […]

A recent Gallup poll data found that nearly 66% of Americans support making cannabis legal. However, this figure was the same as in 2018. This suggests a standstill in the rise in support of cannabis legalization. Moreover, nine states will be voting in 2020 on measures to allow cannabis for recreational or medical use. The […]

During its latest earnings call, Aphria (APHA) stated that vapes and concentrates could form a major share of Canada’s recreational market by 2021.

The spotlight is on marijuana legalization as the demand keeps surging. More states have stepped up to legalize either recreational or medical cannabis.

Aurora Cannabis saw less of an impact from COVID-19 in the third quarter. Cannabis is an essential item amid the pandemic.

As the demand for Cannabis 2.0 products continues to rise, Aurora Cannabis announced the appointment of Miguel Martin as its new chief commercial officer.

Marijuana legalization hopes never really ended in Nebraska. Signature gathering paused in the state amid the pandemic and the lockdown.

Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”

Hexo (TSE:HEXO) has been struggling for a while now and things aren’t looking good. The stock has lost close to 70.2% year-to-date.

Marijuana is gaining a lot of attention amid the coronavirus pandemic. Many people think that Joe Biden should support marijuana legalization.

Amid the coronavirus pandemic, marijuana has become an essential item in many US states. As a result, there was a surge in cannabis demand.

On January 12, GW Pharmaceuticals announced its preliminary unaudited product sales report for the fourth quarter and 2019.

KushCo Holdings reported its Q1 earnings on January 8. KushCo reported revenue of $34.96 million, below analysts’ forecast of $41.5 million.

TerrAscend’s recent private placement was oversubscribed due to strong investor interest. It increased the offering to about $30 million from $20 million.

Aurora Cannabis (ACB) (ACB.TO) is a Canadian cannabis giant, but the company’s plans to enter the US market keep getting delayed.

Jim Cramer expressed disappointment with the cannabis industry, claiming it may not be the “incredible opportunity” he thought it was.

It’s been quite the whipsaw week for cannabis stocks, to put it mildly. First, there was the “Drake spike.” Then came the earnings disappointments.

Canada’s next wave of cannabis legalization allows edibles, beverages, extracts, and topicals on October 17. The products could hit the stores in December.

Aphria (APHA) reported its earnings results for Q4 and fiscal 2019 after the market closed today. Will the positive results lift cannabis sentiment overall?

On Monday morning, OrganiGram’s third-quarter earnings came in as a bit of a let-down. Here’s why.